Braidwell LP
- SEC CIK
- 0001920938
- Latest filing
- Nov 16, 2026
The latest 13F from Braidwell LP covers Q3 2026 (filed Nov 16, 2026): 88 long positions worth $2.41B. The top 10 holdings make up 30.7% of the portfolio, and the largest is Kodiak Sciences Inc. (KOD) at 4.3%. Livermore has 16 filings on Form 13F from this institution, going back to Q4 2022.
What changed in Q3 2026
Full comparisonShare counts compared with Q2 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 14
- Est. +$169.9M
- Added
- 22
- Est. +$166.3M
- Reduced
- 38
- Est. −$611.1M
- Sold out
- 12
- Est. −$191.4M
Top 5 holdings
Share of this quarter's portfolio value
Biggest buys
New and added positions, by estimated amount bought
Largest weight increases
New and added positions, by percentage points of the portfolio gained
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
Metrics
13F metrics for Q3 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $2.41B
- −$294.0M (−10.9%) vs. prior quarter
- Positions
- 88
- +2 vs. prior quarter
- Top 10 concentration
- 30.7%
- Top 10 as share of value
- Turnover
- 13.1%
- Q3 2026, one quarter
- Average holding period
- 6.2 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2022), so positions held before then are understated.
13F filings by quarter
16 quarters, going back to Q4 2022. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $3.53B (Q3 2024)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 16, 2026 | 88 | $2.41B | KODCAIEWTX | vs. Q2 2026 | SEC |
| Q2 2026 | Aug 14, 2026 | 86 | $2.70B | CAIHNGEGKOS | vs. Q1 2026 | SEC |
| Q1 2026 | May 15, 2026 | 88 | $3.00B | CAIGuardant Health, Inc.Repligen Corp | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 17, 2026 | 73 | $3.13B | CAIGuardant Health, Inc.EWTX | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 14, 2025 | 73 | $3.37B | Guardant Health, Inc.CAINovoCure Ltd | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 55 | $2.92B | Guardant Health, Inc.CAINBIX | vs. Q1 2025 | SEC |
| Q1 2025 | May 15, 2025 | 64 | $2.84B | Guardant Health, Inc.NovoCure LtdNBIX | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 14, 2025 | 73 | $3.37B | Guardant Health, Inc.BridgeBio Pharma, Inc.NovoCure Ltd | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 81 | $3.53B | Guardant Health, Inc.BridgeBio Pharma, Inc.NovoCure Ltd | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 75 | $3.19B | Guardant Health, Inc.BridgeBio Pharma, Inc.NovoCure Ltd | vs. Q1 2024 | SEC |
| Q1 2024 | May 15, 2024 | 70 | $3.10B | Guardant Health, Inc.BridgeBio Pharma, Inc.Exact Sciences Corp | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 14, 2024 | 72 | $2.72B | Guardant Health, Inc.BridgeBio Pharma, Inc.Ascendis Pharma A/S | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 14, 2023 | 86 | $3.16B | Guardant Health, Inc.NovoCure LtdAscendis Pharma A/S | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 14, 2023 | 81 | $3.06B | Guardant Health, Inc.Exact Sciences CorpNovoCure Ltd | vs. Q1 2023 | SEC |
| Q1 2023 | May 15, 2023 | 81 | $3.03B | Guardant Health, Inc.Exact Sciences CorpNanostring Technologies Inc | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 14, 2023 | 88 | $2.98B | Guardant Health, Inc.Nanostring Technologies IncNovoCure Ltd | – | SEC |
13D and 13G filings
Companies where Braidwell LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
1 company, largest stake first.
Latest filings
11 filings on file made by Braidwell LP or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| SRZNSurrozen, Inc. | Aug 14, 20264:09 PM ET | 13G/A | 3.90%460.8K shares | −1.60 ppfrom 5.50%Below 5% | Jun 30, 2026 | SEC |
| AMANAmanat Acquisition Corp. | Aug 14, 20264:06 PM ET | 13G | 9.30%700.0K shares | New | Jun 30, 2026 | SEC |
| SRZNSurrozen, Inc. | Feb 17, 20264:48 PM ET | 13G | 5.50%470.0K shares | New | Dec 31, 2025 | SEC |
| DBVTDBV Technologies S.A. | Feb 14, 20254:25 PM ET | 13G/A | 2.50%2.39M shares | –Below 5% | Dec 31, 2024 | SEC |
| DBVTDBV Technologies S.A. | Nov 14, 2024 | 13G/AOld format | – | – | – | SEC |
| DCPHDeciphera Pharmaceuticals, Inc. | Feb 14, 2024 | 13G/AOld format | – | – | – | SEC |
| DBVTDBV Technologies S.A. | Feb 14, 2024 | 13G/AOld format | – | – | – | SEC |
| CRNXCrinetics Pharmaceuticals, Inc. | Feb 14, 2024 | 13G/AOld format | – | – | – | SEC |
| DBVTDBV Technologies S.A. | Feb 14, 2023 | 13GOld format | – | New | – | SEC |
| CRNXCrinetics Pharmaceuticals, Inc. | Feb 14, 2023 | 13GOld format | – | New | – | SEC |
| DCPHDeciphera Pharmaceuticals, Inc. | Feb 14, 2023 | 13GOld format | – | New | – | SEC |